Guardant360 CDx (Guardant Health, Inc.), also based on NGS, can detect abnormalities in NSCLC, including ALK rearrangement and KRAS p.G12C (Bauml et al., 2022; Kwon et al., 2022). This evidence concerns the gene ALK and non-small cell lung carcinoma.